Sometime back, we covered Deciphera (DCPH), which is targeting tyrosine kinase inhibitors or TKI resistance through inhibition of "switch pocket," a specific area which stabilizes the active kinase. Inhibiting this destabilizes the active kinase, thus bypassing secondary kinase resistance. We then said that Blueprint Medicines Corporation (BPMC), which has a differentiated approach to TKI resistance, is DCPH's main competition. In this article, we will take a look at BPMC as an investment hedge in the TKI resistance arena. While BPMC has two marketed products and a second product in late-stage development